ArticleBritish journal of clinical pharmacology2016
Usage patterns of paracetamol in France.
Article in British journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Trial
- Automated Risk Assessment of Opioid Use: Analysis Using Pre-Trained Transformers on Social Media Data.JMIR infodemiology · 2026Article
- Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: A nationwide cohort study.PloS one · 2024Article
- Exploring Perceptions About Paracetamol, Tramadol, and Codeine on Twitter Using Machine Learning: Quantitative and Qualitative Observational Study.Journal of medical Internet research · 2023Observational
- A pill as a quick solution: association between painkiller intake, empathy, and prosocial behavior.Scientific reports · 2023Article
- Impact of acetaminophen product labelling changes in Canada on hospital admissions for accidental acetaminophen overdose: a population-based study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Article
- Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal.Basic & clinical pharmacology & toxicology · 2022Review
- Comparison of paracetamol and diclofenac prescribing preferences for adults in primary care.Primary health care research & development · 2021Article
- Assessing Patient Perceptions and Experiences of Paracetamol in France: Infodemiology Study Using Social Media Data Mining.Journal of medical Internet research · 2021Article
- Paracetamol Intake and Hematologic Malignancies: A Meta-Analysis of Observational Studies.Journal of clinical medicine · 2021Review
- National Poison Center Calls Before vs After Availability of High-Dose Acetaminophen (Paracetamol) Tablets in Switzerland.JAMA network open · 2020Article
- Does Ibuprofen Worsen COVID-19?Drug safety · 2020Article
- Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.Drug safety · 2020Review
- Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.Drug safety · 2019Article
- Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.Drug safety · 2018Article
- Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe.British journal of clinical pharmacology · 2018Article
- Use of analgesics in France, following dextropropoxyphene withdrawal.BMC health services research · 2018Article
- Health Data for Public Health: Towards New Ways of Combining Data Sources to Support Research Efforts in Europe.Yearbook of medical informatics · 2017Article
- Usage patterns of paracetamol in France.British journal of clinical pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of the present study was to describe the real-life usage patterns of paracetamol.
methodsThe Echantillon Généraliste de Bénéficiaires (EGB) database, the permanent 1/97 representative sample from the French national healthcare insurance system, was searched in 2011 to identify usage patterns, concomitant chronic diseases and use of cardiovascular medication in users prescribed single-ingredient (SP) and combination (CP) paracetamol, representing 85% of all sales.
resultsOf 526 108 subjects aged ≥15 years in the EGB, 268 725 (51%) had paracetamol dispensed on ≥1 occasion; of these, 207 707 (77%) were dispensed only SP and 61 018 (23%) received CP with or without SP. SP users were younger (48.3 years vs. 50.5 years), and 57% of SP users vs. 58% of CP users were female. Chronic comorbidities were more common in CP than SP users. SP users had, on average, 3.4 dispensings per year vs. 5.0 for CP users, for 36 defined daily doses (DDD, 3 g) of SP vs. 53 DDD per year for CP; 49% SP users bought 14 DDD or fewer; 15% bought >60 DDD. Use of paracetamol increased with age from about 16 DDD per year in 15-30-year-olds to over 90 DDD per year in patients above the age of 75; 53% of patients ≤60 years bought fewer than 14 DDD per year, whereas 55% of those >60 bought more than 30 DDD per year. More than half the dispensings exceeded the legal per-box limit of 8 g.
conclusionsOver 50% of the French adult population were dispensed paracetamol at least once over the course of a year, generally for short-term use. Considering recent misgivings on the real efficacy and safety of paracetamol, such widespread use might have important public health consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.